Here's Why Hold Strategy Is Apt for Core Laboratories Stock for Now

CLB benefits from long-term industry investments and strong acquisitions, though its growth is modest and vulnerable to macroeconomic and geopolitical uncertainties.

Zacks Investment Research • Dec 3, 2025

Core Laboratories Q3 Earnings Surpass Estimates, Decline Y/Y

CLB beats Q3 earnings estimates on strong Production Enhancement results. However, earnings dip y/y due to the Reservoir Description segment's weakness.

Zacks Investment Research • Oct 24, 2025

Core Laboratories Inc. (CLB) Q3 2025 Earnings Call Transcript

Core Laboratories Inc. (NYSE:CLB ) Q3 2025 Earnings Call October 23, 2025 8:30 AM EDT Company Participants Lawrence Bruno - Chairman of the Board, CEO, President & COO Gwendolyn Schreffler - Senior Vice President of Corporate Development & Investor Relations Chris Hill - Senior VP & CFO Conference Call Participants John Daniel - Daniel Energy Partners, LLC Presentation Operator Good day, and welcome to the Core Laboratories Q3 2025 Earnings Call. [Operator Instructions] Please note, this event is being recorded.

Seeking Alpha • Oct 23, 2025

Compelling Value In Small-Cap Equities And Select Cyclicals

Supplier of residential thermal, comfort and security solutions, Resideo Technologies, Inc. (REZI) was the top contributor in the quarter. Shares of gold mining company, Barrick Mining Corporation (B) also jumped in the quarter on strong financial results buoyed by rising gold prices. We added Arthur J. Gallagher & Co. (AJG), the world's largest insurance broker focused on middle-market clients.

Seeking Alpha • Oct 24, 2025

CORE LAB REPORTS THIRD QUARTER 2025 RESULTS

HOUSTON, Oct. 22, 2025 /PRNewswire/ -- Core Laboratories Inc. (NYSE: "CLB") ("Core", "Core Lab", or the "Company") reported third quarter 2025 revenue of $134,500,000. Core's operating income was $20,900,000, with earnings per diluted share ("EPS") of $0.30, all in accordance with U.S. generally accepted accounting principles ("GAAP"). Operating income, ex-items, a non-GAAP financial measure, was $16,600,000, yielding operating margins of 12%, sequential incremental margins of 48%, and EPS, ex-items, of $0.22. A full reconciliation of non-GAAP financial measures is included in the attached financial tables.

PRNewsWire • Oct 22, 2025

Core Laboratories (CLB) Beats Q3 Earnings and Revenue Estimates

Core Laboratories (CLB) came out with quarterly earnings of $0.22 per share, beating the Zacks Consensus Estimate of $0.19 per share. This compares to earnings of $0.25 per share a year ago.

Zacks Investment Research • Oct 22, 2025

Core Laboratories to Post Q3 Earnings: Key Metrics to Watch

CLB is set to post Q3 earnings amid volatile oil markets, with estimates hinting at lower revenues and profit declines.

Zacks Investment Research • Oct 16, 2025

Core Laboratories (CLB) Expected to Beat Earnings Estimates: Should You Buy?

Core Laboratories (CLB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Oct 15, 2025

Strength Seen in Core Laboratories (CLB): Can Its 6.0% Jump Turn into More Strength?

Core Laboratories (CLB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Investment Research • Oct 14, 2025

Here's Why Holding Core Laboratories Stock Is Justified for Now

CLB benefits from revenue expansion, proprietary tools & disciplined spending, though flat guidance, low dividends & sector competition remain headwinds.

Zacks Investment Research • Oct 6, 2025